SOHO State of the Art Updates and Next Questions | The Current State of CAR T-Cell Therapy and Bispecific Antibodies in Mantle Cell Lymphoma

Jonathan M Weiss; Tycel J Phillips

doi:10.1016/j.clml.2024.10.009

SOHO State of the Art Updates and Next Questions | The Current State of CAR T-Cell Therapy and Bispecific Antibodies in Mantle Cell Lymphoma

Clin Lymphoma Myeloma Leuk. 2024 Oct 16:S2152-2650(24)02380-2. doi: 10.1016/j.clml.2024.10.009. Online ahead of print.

Authors

Jonathan M Weiss¹, Tycel J Phillips²

Affiliations

¹ Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI.
² Department of Hematology and Hematopoietic Cell Transplantation, Division of Lymphoma, City of Hope Comprehensive Cancer Center, Duarte, CA. Electronic address: tphillips@coh.org.

PMID: 39523133
DOI: 10.1016/j.clml.2024.10.009

Abstract

MCL remains incurable, and patients who relapse post BTK inhibitors have poor outcomes. BsAbs and CAR T cell therapy are novel strategies to treat patients with R/R MCL. These therapies exhibit favorable outcomes and side effect profiles in a previously dismal space. This review looks to detail the current data available for BsAbs and CAR T cell therapy in R/R MCL, and how are current treatment paradigm is shifting to incorporate these novel agents.

Keywords: CD19; CD20; CD3; Immunotherapy; Lymphoma; Novel.

Publication types

Review